University of California

Xoma Technology Ltd.

Xoma (US) LLC

Musc Foundation for Research Development

Ou Li

Amer M Mirza

Kirk William Johnson

Toshihiko Takeuchi

Daniel H Bedinger

Hassan Issafras

Rosemary J Akhurst

Marina Roell

Agnes Choppin Holmes

Mark Rubinstein

Lauren Schwimmer

Hoa Giang

Llewelyn Lao

Kristin Camfield Lind

John Corbin

Kiranjit Kaur Ahluwalia

Paul Rubin

Ira Goldfine

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF&#x3b2;) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.

Method of increasing the ratio of effector T cells to regulatory T cells in a tumor by administering to a subject a TGF-beta inhibitor and a PD-1 antibody

Treatment of cancer using anti-TGF-&#x3b2; and anti-PD-1 antibodies

The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.

Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia

Treatment of cancer using anti-TGF-BETA and PD-1 antibodies

Growing community of inventors

Dublin, CA, United States of America

Ou Li